Myeloid Leukemias: A Glance at Middle Eastern Centers

References

• Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502–513. doi:10.1038/nrc84012094236
   PubMed Web of Science ®Google Scholar
• Mastuno N, Osato M, Yasmashita N, et al. Dual mutations in the AML1 and FLT3genes are assoicated with leukaemogenesis in acute myeloblastic leukaemia of the M0 subtype. Leukaemia. 2003;17:2492–2499. doi:10.1038/sj.leu.2403160
   Web of Science ®Google Scholar
• Ramsey H, Zhang D-E, Richkind K, et al. Fusion of AML1/Runx1to CopineVIII, a novel member of the copine family, in an aggressive acute myelogenous leukaemia with t(12;21)translocation. Leukaemia. 2003;17:1665–1685. doi:10.1038/sj.leu.2403048
   Web of Science ®Google Scholar
• Khaled SA, Burthem J, Abo ElNoor E, et al. Differences between nucleophosmin isoforms in de-novo acute myeloid leukemia: possible implications in developing targeted therapy for acute myeloid leukemia with normal karyotype. Egyptian J Hematol. 2015;40(41):190–194. doi:10.4103/1110-1067.170220
   Google Scholar
• Khaled SA, Burthem J, Abo ElNoor E, et al. Role of nucleophosmin gene mutation in leukemogenesis of acute myeloid leukemia. J Hematol. 2018;7(1):7–13. doi:10.14740/jh365w
   Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.19357394
   PubMed Web of Science ®Google Scholar
• Chang KL, Weiss LM. Lymph Nodes in Modern Surgical Pathology by Noel Weidner, Richard J. Cote, Saul Suster, and Lawrence M. Weiss (Second Ed.). Elsevier Inc; 2009.
   Google Scholar
• Najfeld V. Conventional and Molecular Cytogenomic Basis of Hematologic Malignancies in Hematology (Ebook Seventh Edition), 2018. In: Hoffman R, Benz EJ, Jr, Abutalib SA, editors. New York: Elsiever Inc.; 2018.
   Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105(11):1684–1692. doi:10.1038/bjc.2011.45022045184
   PubMed Web of Science ®Google Scholar
• Cosmai L, Mourizio O. Gallieni, Acute Kidney Injury in Oncology and Tumor Lysis Syndrome in Critical Care Nephrology (Ebook Third Edition). Elsiever Inc; 2019:234–250.
   Google Scholar
• Jacqueline M, Junkins –hopkins JL, Klaus J, et al. Hematopoietic Neoplasms in Dermatopathology. ebook1sted. Saunders/Elsiever Inc;2010.
   Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012;87:1037–1045. doi:10.1002/ajh.v87.1123090888
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Do¨hner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG trial AML HD98B. Haematol`ogica. 2009;94(1):54–60.
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemia treated with imatinib in a single center: a 4.5-year follow up. Cancer. 2005;103:1659–1669. doi:10.1002/cncr.2092215747376
   PubMed Web of Science ®Google Scholar
• Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology cancer. Cancer. 2006;107(9):2099–2107. doi:10.1002/cncr.2223317019734
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lazarevic V, Horstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–9.29. doi:10.1182/blood-2011-12-37900822383796
   PubMed Web of Science ®Google Scholar
• Khaled SA, Burthem J, Abo ElNoor E, et al. The mutated cytoplasmic form of nucleophosmin expressed by the cell line OCI-AML3 is phosphorylated on Thr199: implications for the pathogenesis of primary acute myeloid leukaemia (AML). Available from: https://www.eposters.net/poster/the-mutated-cytoplasmic-form-of-nucleophosmin. Accessed 604, 2019.
   Google Scholar
• Hehlmann R, Hauchhaus A, Baccarani M. Chronic myeloid leukemia. Lancet. 2007;370:342–350. doi:10.1016/S0140-6736(07)61165-917662883
   PubMed Web of Science ®Google Scholar
• Cancer research Uk. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cml/incidence. Accessed 3, 2019.
   Google Scholar
• Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish acute leukemia registry. Am J Hematol. 2015;90(3):208–14.26. doi:10.1002/ajh.2390825421221
   PubMed Web of Science ®Google Scholar
• Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;3:268.27. doi:10.3389/fgene.2012.00268
   Google Scholar
• Ries LAG EM, Eisner MP, Kosary CL, et al. Edwards BK (Eds). SEER Cancer Statistics Review, 1975–2002. Bethesda, MD:National Cancer Institute; 2005 Available from: https://seer.Cancer.gov/csr/1975_2002/. Based on November 2004 SEER data submission, posted to the SEER website.
   Google Scholar
• Xie Y, SM D, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973–1998). Cancer. 2003;97:2229–2235. doi:10.1002/cncr.1131612712476
   PubMed Web of Science ®Google Scholar
• The incidence of acute myeloid leukemia … (PDF Download Available). Available from: https://www.researchgate.net/publication/318990878_The_incidence_of_acute_myeloid_leukemia_in_Calgary_Alberta_Canada_A_retrospective_cohort_study. Accessed 404, 2018.
   Google Scholar
• Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast England. Haematologica. 2006;91(10):1400–4. 26.17018393
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113(18):4179–4187. doi:10.1182/blood-2008-07-17200719008455
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. doi:10.1056/NEJMoa06286717151364
   PubMed Web of Science ®Google Scholar
• Khan MQ, Shivarudrappa AS, el-Bialy S, et al. Leukemia cases in central Hospital Riyadh (Saudi Arabia). J Indian Med Assoc. 1991;89(2):38–42.2056174
   PubMedGoogle Scholar
• Azzazi MO, Fahmy O, Mattar M, et al. Second report of arab leukemia net (ALN) registry for chronic myeloid leukemia (CML) in the Middle East &North Africa Region (AFME). Epidemiology of CML and Additional Chromosomal Abnormalities (ACAs) in Egypt, Multicenter Results. Blood. 2014;124(21):5539. doi:10.1182/blood.V124.21.5539.5539
   Web of Science ®Google Scholar
• Hassan IB, Islam SI, Alizadeh H, et al. Acute leukemia among the adult population of United Arab Emirates: an epidemiological study. Leuk Lymphoma. 2009;50(7):1138–1147. doi:10.1080/1042819090291918419557635
   PubMed Web of Science ®Google Scholar
• Allahyari A, Tajeri T, Sadeghi M. Prognostic factors and survival in acute myeloid leukemia cases a report from the Northeast of Iran. Asian Pac J Cancer Prev. 2016;17(3):1547–1551. doi:10.7314/APJCP.2016.17.3.154727039804
   PubMedGoogle Scholar
• Al-Bahar S, Pandita R, Al-Muhannaha A, et al. The epidemiology of leukemia in Kuwait. Leuk Res. 1994;18(4):251–255. doi:10.1016/0145-2126(94)90027-28170169
   PubMed Web of Science ®Google Scholar
• Pavlova M. Europe is going grey: can EU countries work together to care for their elderly? Available from: https://theconversation.com/europe-is-going-grey-can-eu-countries-work-together-to-care-for-their-elderly-80416. Accessed 64, 2019.
   Google Scholar
• Kav S, Tokdemir G, Tasdemir R, et al. Patients with cancer and their relatives beliefs, information needs and information –seeking behaviour about cancer and treatment. Asian Pac J Cancer Prev. 2012;13:6027–6032. doi:10.7314/APJCP.2012.13.12.602723464398
   PubMedGoogle Scholar
• Taha NM, Zatton HK, Zatton HI. Nurses knowledge and practice regarding educational needs for patients with leukemia. J Nurse Care. 2017;6:406–413.
   Google Scholar
• Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222–231. doi:10.1016/S1470-2045(08)70032-918282806
   PubMed Web of Science ®Google Scholar
• Smith RE, Bryant J, DeCillis A, et al. National surgical adjuvant breast and bowel project experience. acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol. 2003;21(7):1195–1204. doi:10.1200/JCO.2003.03.11412663705
   PubMed Web of Science ®Google Scholar
• Carli PM, Sgro C, Parchin-geneste N, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia. 2000;14:1014–1017. doi:10.1038/sj.leu.240178710865966
   PubMed Web of Science ®Google Scholar
• Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol. 1996;9:57–85. doi:10.1016/S0950-3536(96)80037-08730551
   PubMed Web of Science ®Google Scholar
• Kachuri L, Harris MA, MacLeod JS, et al. Cancer risks in a population based study of 70, 750 agricultural workers : results from the Canadian census of health and environment cohort (CanCHEC). BMC Cancer. 2017;17(1):343. doi:10.1186/s12885-017-3346-x28525996
   PubMed Web of Science ®Google Scholar
• Khaled SA. Treatment with tyrosine kinase inhibitors in chronic myeloproliferative neoplasms: pros and cons. Am J Intern Med. 2016;4(4):66–74. doi:10.11648/j.ajim.20160404.12
   Google Scholar
• Kantarijian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:2-year follow-up from a randomized phase 3 trial(DASISION). Blood. 2012;119(5):1123–1129. doi:10.1182/blood-2011-08-37608722160483
   PubMed Web of Science ®Google Scholar
• Mahmoud H, El-Haddad A, Fahmy O, et al. Hematopoietic stem cell transplantation in Egypt. Bone Marrow Transplant. 2008;42(Suppl 1):S76–S80. doi:10.1038/bmt.2008.13618724311
   PubMed Web of Science ®Google Scholar
• Visser O, Trama A, Maynadié M, et al. Incidence, survival, and prevelance of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257–3266. doi:10.1016/j.ejca.2012.05.02422770878
   PubMed Web of Science ®Google Scholar
• Zayed HA, Saied SM, El-Sallamy RM, et al. Knowledge, attitudes and practices of safe handling of cytotoxic drugs among oncology nurses in tanta university hospitals. Egypt J Occup Med. 2019;43(1):75–92. doi:10.21608/ejom.2019.25119
   Google Scholar